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Edited by Gianni CesareniAbstract The 14-3-3 proteins are known to interact with a
number of proteins involved in the regulation of cell signaling.
Here, we describe an association of 14-3-3f with the epidermal
growth factor receptor (EGFR) that is rapidly induced by EGF.
The 1028-EGFR truncated mutant which lacks the cytoplasmic
tail from amino acids 1029–1186 identiﬁed the binding site for
14-3-3 to be between amino acid 1028 and the receptor carboxyl
terminus. Mutational deletion of serine residues 1046, 1047,
1057 and 1142 did not inhibit EGF-induced 14-3-3 association
with the receptor. Immunoﬂuorescence microscopy indicated an
EGF-induced co-localization of EGFR and HA-14-3-3f along
the plasma membrane. Our ﬁnding adds to the growing
complexity of EGF receptor signaling and indicates a role for
14-3-3 proteins in EGF receptor signaling or regulation.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Signal transduction1. Introduction
The epidermal growth factor receptor (EGFR) belongs to
the large family of cell surface receptors with intrinsic tyrosine
kinase activity. The 175 kDa receptor is composed of an ex-
tracellular ligand binding domain, a single membrane span-
ning region, and an intracellular tail containing the tyrosine
kinase domain and multiple binding sites for signaling mole-
cules [1]. Following binding of EGF, the receptor dimerizes,
autophosphorylates, and then nucleates signaling complexes.
Numerous substrates of EGFR have been identiﬁed, including
Grb2 [2], Shc [3], c-Cbl [4], PLCc1 [5], and Gab1 [6].
The 14-3-3 family of proteins are ubiquitously expressed and
involved in the regulation of diverse intracellular processes of
several signaling proteins in all eukaryotic organisms [7].
Important 14-3-3-mediated activities include regulation of cell
cycle arrest, intracellular signaling in response to stress, pho-
toreceptor development and learning in Drosophila, and sig-
naling from Ras/Raf [9,11–13]. There are seven known
mammalian 14-3-3 isoforms (b, r, e, f, g, r, and s) with
molecular masses of 28–33 kDa. The 14-3-3 proteins are evo-
lutionary highly conserved from yeast to mammals and the* Corresponding author. Fax: +47-23071511.
E-mail address: m.p.oksvold@labmed.uio.no (M.P. Oksvold).
0014-5793/$22.00  2004 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2004.05.068diﬀerent 14-3-3 isoforms display a high level of homology [8].
The 14-3-3 proteins are adaptor and scaﬀolding proteins that
interact with proteins containing distinct phosphoserine/thre-
onine motifs [10]. 14-3-3 can also form complexes with non-
phosphorylated proteins [8]. In addition, two serine and one
threonine phosphorylation sites on 14-3-3f have been identi-
ﬁed [11]. 14-3-3 can regulate its binding partners by altering
their intracellular localization, catalytic activity or complex
formation with other proteins [9,14]. Here, we show that
stimulation of cells with EGF induces binding of 14-3-3f to the
EGFR carboxy-terminal tail, however the functional relevance
of this complex formation remains to be determined.2. Materials and methods
2.1. Materials
The aﬃnity puriﬁed rabbit anti-14-3-3 antibody was a kind gift from
M. Guthridge and A.F. Lopez. The antibody was raised in New
Zealand White rabbits using glutathione S-transferase-14-3-3f (GST-
14-3-3f) as the immunogen [15]. Puriﬁed human 14-3-3f was obtained
from F.C. Stomski and A.F. Lopez. The expression vector for HA-
tagged 14-3-3f (pEF/HA-14-3-3fÞ was obtained from R. Marais. A
rabbit anti-14-3-3 antibody recognizing all 14-3-3 isoforms was pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA). Monoclonal
anti-HA (12CA5) was obtained from Roche (Indianapolis, IN). A
sheep anti-EGFR antibody was purchased from Fitzgerald Industries
(Concord, MA). The R42/pY1173 rabbit antisera are speciﬁc to
phosphorylated Tyr1173 in EGFR and have previously been described
[24]. Cy3-conjugated donkey anti-sheep and Cy2-conjugated donkey
anti-mouse and peroxidase-conjugated donkey anti-mouse and anti-
sheep antibodies were purchased from Jackson (West Grove, PA).
Electrophoresis reagents were purchased from BioRad (Hercules, CA).
Lipofectamine was obtained from Invitrogen (Carlsbad, CA). All
other reagents were purchased from Sigma Chemical Company (St.
Louis, MO), unless otherwise stated.
2.2. Cell culture and transfection
The mouse ﬁbroblast NIH3T3 cells were obtained from ATCC and
cultured in DMEM (Trace Biochemicals) containing 10% FCS (Gibco-
BRL) and2mML-glutamine (TraceBiochemicals) at 37 Cand5%CO2.
Cells were stably transfected with human full length EGFRby retroviral
infection, as described earlier [16]. A truncated form of EGFR (1028-
EGFR) was generated by site directed mutagenesis to introduce stop
codons at amino acids 1029 of the human EGFR, and transfection by
retroviral infection was performed as previously described [16]. The
EGFR serine mutants (S1046A/S1047A and S1046A/S1047A/S1057A/
S1142A) were expressed in the pLEN vector, as described earlier [17].
The vector control and the mutants were stably transfected by retroviral
transfection into NIH3T3 cells under selection by G418 [16]. All con-
structs were examined by automated DNA sequencing (373 ABI).
2.3. Western immunoblotting and co-immunoprecipitation
Cells growing in Petri dishes were starved in 0.5% FCS overnight
and incubated or not in 10 nM human recombinant EGF. Cells wereblished by Elsevier B.V. All rights reserved.
Fig. 1. Eﬀect of EGF on 14-3-3 binding to the EGFR. EGFR im-
munoprecipitates from HeLa cells untreated (C) or stimulated with
EGF (E) for 0.5 and 2 min were analyzed by Western immunoblotting.
Rabbit anti-14-3-3 (A), rabbit anti-pY1173, and sheep anti-EGFR
antibodies were used. The markers at left indicate 30 and 220 kDa.
208 M.P. Oksvold et al. / FEBS Letters 569 (2004) 207–210rinsed in ice-cold PBS and lysed in Tris lysis buﬀer, pH 7.4 (50 mM
Tris–HCl, 150 mMNaCl, 1 mM EDTA, 1% NP-40, 1 mMNa3VO4, 20
mM NaF, and 1 lg/ml chymostatin, leupeptin and antipain). Lysates
were incubated on ice for minimum 15 min, and cell debris and nuclei
were removed by centrifugation. For analysis of total cell lysates, a 5
protein sample buﬀer stock solution (2% SDS, 10% glycerol, 0.02%
bromophenol blue and 2% b-mercaptoethanol ﬁnal concentrations)
was mixed with the lysate. The samples were boiled for 5 min. For co-
immunoprecipitation, 50 ll protein A–Sepharose (Amersham
Biosciences, Uppsala, Sweden) was incubated with 2 ll monoclonal
anti-EGFR (Santa Cruz Biotechnology) in 50 mM Tris, pH 7.2, for 2
h. Lysates were incubated with pre-washed protein A–Sepharose-anti-
EGFR complex for 1 h on ice and washed three times with 25 mM
Tris, pH 7.2. Samples were resuspended in 90 ll Laemmli sample
buﬀer, pH 7.4 (10 mM Tris, 10% v/v glycerol, 2% w/v SDS, 5 mM
EDTA, 0.02% bromophenol blue, and 2% b-mercaptoethanol), and
boiled for 5 min. Samples were analyzed by SDS–PAGE with 6% or
10% acrylamide gels. Proteins were transferred semidry to nitrocellu-
lose membranes, rinsed in ice-cold Tris-buﬀered saline [TBS; 10 mM
Tris, pH 8.0, and 150 mM NaCl] and incubated in blocking buﬀer
(TBS containing 5% dried milk, 1 mM NaF, and 1 mM Na3VO4) for
1 h at 4 C. The membranes were incubated overnight at 4 C with
rabbit anti-14-3-3f (EB1), sheep anti-EGFR, or rabbit anti-pY1173
EGFR. Proteins were detected using HRP-conjugated secondary an-
tibodies for 90 min at RT. All antibodies were diluted in TBS con-
taining 1% w/v dry milk (Bonlac Foods, Melbourne, Australia) and
0.01% thimerosal. The ﬁlters were washed in TBS and antigens were
visualized by the enhanced chemiluminescence (ECL) method with
Hyperﬁlm MP (Amersham Biosciences).
2.4. Filter binding of 14-3-3f
Total cell lysates were separated by SDS–PAGE as described. Pro-
teins were transferred to a nitrocellulose membrane and incubated with
5% dried milk in TBS with 1 mMNa3VO4 and 10 mMNaF for 30 min.
The membrane was probed with 2 lg/ml 14-3-3f in the same solution
at 4 C for 4 h prior to an 8 2 min wash in TBS. The membrane was
incubated with 14-3-3 antibodies (EB1) at 4 C overnight and pro-
cessed as described earlier for Western immunoblotting analysis.
2.5. Immunoﬂuorescence microscopy
HeLa cells cultured in 60-mm plastic dishes were washed in PBS and
ﬁxed in ice-cold methanol for 4 min. Cells were incubated with primary
antibodies overnight, followed by Cy2- and Cy3-conjugated donkey
antibodies to IgG of the appropriate species. All dilutions were in PBS
containing 1% BSA. Cells were studied in a Leica TCS SP confocal
microscope equipped with an Ar (488 nm) and two He/Ne (543 and
633 nm) lasers. A Plan apochromat 100/1.4 oil objective was used.
Images were acquired sequentially.Fig. 2. Detection of 14-3-3f binding by ﬁlter binding. Total lysates
from NIH3T3-EGFR cells untreated (C) or stimulated with EGF for
0.5 and 2 min were separated by SDS–PAGE and transferred to ni-
trocellulose ﬁlter. Following blocking, the ﬁlter was incubated with
puriﬁed 14-3-3f protein (2 lM) for 4 h at 4 C. The ﬁlter was rinsed in
TBS and immunoblotted with an aﬃnity puriﬁed rabbit anti-14-3-3
antibody. Total lysates were also analyzed with a sheep anti-EGFR
antibody to demonstrate equal protein levels. The markers at left in-
dicate 220 kDa.3. Results and discussion
In order to identify interaction between the EGFR and
members of the 14-3-3 protein family, EGFR was immuno-
precipitated from HeLa cell lysates derived from cells that had
been treated with or without EGF. Immunoblotting with a
polyclonal anti-14-3-3 pan antibody speciﬁcally recognized a
band at the appropriate molecular mass in cells stimulated
with EGF (Fig. 1). The interaction was detected shortly after
exposure to EGF (0.5 min). Analyses of cell extracts after
immunoprecipitation of the EGFR by immunoblotting with
the anti-14-3-3 pan antibody did not display any obvious dif-
ferences in 14-3-3 levels in control cells and EGF-stimulated
cells (data not shown). This indicates that the fraction of total
14-3-3 that is co-immunoprecipitated with the EGF-activated
EGFR is low. From these results we hypothesized that EGFR
and 14-3-3 form a complex in response to EGF-stimulation.
Among the seven known mammalian 14-3-3 isoforms, we de-
cided to study the 14-3-3f isoform and possible interaction
with the EGFR in more detail. 14-3-3f binds to severaldiﬀerent enzymes and has a role in the Ras-Raf-MEK-MAPK
signaling pathway [9]. We tested whether the 14-3-3f isoform
associates with the EGFR by ﬁlter binding. Total cell lysates
from control and EGF-stimulated NIH3T3 cells overexpress-
ing the human EGFR were separated by SDS–PAGE and
transferred to ﬁlter. Following blocking, the ﬁlter was incu-
bated with puriﬁed 14-3-3f protein for 4 h, before rinsing and
incubation with the anti-14-3-3 pan antibody. The 14-3-3f
protein was detected at a molecular weight corresponding to
the EGFR in lysates from cells stimulated with EGF and not
in unstimulated cells (Fig. 2). These ﬁndings indicate that the
EGFR is capable of interacting directly with 14-3-3f.
Fig. 3. Analysis of 14-3-3f binding to EGFR truncation mutants. Total
lysates from NIH3T3-EGFR cells (wt) and NIH3T3 cells expressing
the 1028-EGFR truncation mutant (1028) were examined by ﬁlter
binding. Lysates from untreated cells (C) or cells stimulated with EGF
for 2 min (E2) were separated by SDS–PAGE and transferred to ni-
trocellulose ﬁlter. The ﬁlter was analyzed by immunoblotting with a
rabbit anti-14-3-3 antibody (top panel) and a sheep anti-EGFR anti-
body (bottom panel). The markers at left indicate 220 kDa.
Fig. 4. Analysis of 14-3-3f binding to EGFR serine mutants. Total
lysates from NIH3T3 cells expressing wild-type EGFR (wt), an EGFR
serine double mutant (DM; with serine residues 1046 and 1047 re-
moved) and an EGFR serine quadruple mutant (QM; with serine
residues 1046, 1047, 1057 and 1142 removed) were examined. Lysates
from untreated cells (C) or cells stimulated with EGF for 0.5 min were
separated by SDS–PAGE and transferred to nitrocellulose ﬁlter. The
ﬁlter was analyzed by immunoblotting with a rabbit anti-14-3-3 anti-
body (top panel), a rabbit anti-pY1173 antibody (middle panel), and a
sheep anti-EGFR antibody (bottom panel). The markers at left indi-
cate 220 kDa.
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mation on truncated receptors was examined. We took ad-
vantage of NIH3T3 cells stably expressing the human
truncation mutant 1028-EGFRwhich has the carboxy-terminalTable 1
Binding preferences of 14-3-3 and proposed 14-3-3 binding motif in the
processed EGFR
14-3-3 binding preferences: RSX(pS/T)XP or RXXX(pS/T)XP
Sequence Protein
(1040)SFLQRYSSDPTGAL EGFR human
(1040)AFLQRYSSDPTGAV EGFR mouse
(1086)SPLQRYSEDPTVPL ErbB2 human
(1079)KDGNRLSQPPNCSQ Let-23 C-elegans
Fig. 5. Immunolocalization of EGFR and 14-3-3f. HeLa cells were transfected
10 nM EGF for 1 min (D–F). A sheep anti-EGFR followed by Cy3-conjugat
followed by Cy2-conjugated donkey anti-mouse (B and E; red) were appliedresidues 1029–1186 removed [16]. Anti-EGFR immunoprecip-
itates from control and EGF-stimulated cells expressing
wild-type and 1028-EGFR was analyzed by ﬁlter binding with
14-3-3f. As seen in Fig. 3, complex formation between the
truncated receptor and 14-3-3f was not detected. Our results
suggest that the carboxy-terminal domain of the EGFR is in-
volved in the interaction with 14-3-3f, either directly, or indi-
rectly involving another unknown kinase. When searching for
potential interaction sites in this receptor domain, we found awith a HA-tagged 14-3-3f and left untreated (A–C) or stimulated with
ed donkey anti-sheep antibody (A and D; green) and a mouse anti-HA
for detection. Bar, 10 lm.
210 M.P. Oksvold et al. / FEBS Letters 569 (2004) 207–210serine-containing sequence that resembles the known binding
preferences for 14-3-3 [10,18]. The 14-3-3 binding preference
sequences and the proposed 14-3-3 binding sequence in human
EGFR and additional species are presented in Table 1. To test
the relevance of serine residues 1046 and 1047 (S1046, S1047) in
14-3-3 interaction, S1046 and S1047 were altered by site-di-
rected mutagenesis to alanine. Analysis of EGFR immuno-
precipitates from NIH3T3 cells stably expressing the wild-type
EGFR and the S1046A/S1047A mutant by ﬁlter binding with
14-3-3f revealed that the mutant receptor did not exhibit a
diﬀerent 14-3-3 binding pattern in comparison to the wild-type
EGFR (Double Mutant in Fig. 4). Two additional serine resi-
dues in the carboxy-terminal tail of the receptor were also
mutated (S1057A and S1142A) without any eﬀects on 14-3-3
binding to the EGFR (QM in Fig. 4). Although these experi-
ments do not locate the exact binding site for 14-3-3 in the
EGFR, they provide further proof that 14-3-3 proteins can
bind to a variety of proteins without known 14-3-3 binding
preference motifs [19–21] as well as non-phosphorylated pro-
teins [22,23].
We utilized immunoﬂuorescence microscopy to study the
EGF-induced re-distribution of 14-3-3f and possible interac-
tion with the EGFR. Cells were transfected with an HA-tagged
14-3-3f using Lipofectamine (Invitrogen) 24 h prior to exper-
iments. In unstimulated cells 14-3-3f was located throughout
the cytosol, whereas EGFR was found mainly in the plasma
membrane (Fig. 5A–C). After stimulation with EGF for 1 min,
we observed a redistribution of 14-3-3f to the plasma mem-
brane where it was co-localized with the EGFR (Fig. 5D–F).
In summary, our results show that 14-3-3f can interact with
the EGFR through an activation-dependent mechanism. We
also determined that the 14-3-3f-EGFR association involves
the carboxy-terminal receptor domain, but the exact interac-
tion site remains to be identiﬁed.
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